Article

The association between medroxyprogesterone acetate exposure and cerebral meningioma among a Medicaid population

2025-06-27

Abstract excerpt

<h4>ABSTRACT</h4> <h4>BACKGROUND</h4> Medroxyprogesterone acetate (MPA) is a synthetic contraceptive that can be used orally or as a once-every-three-month injection (i.e., depot MPA [dMPA]). Prior research has reported an increased association between dMPA and cerebral meningioma, a cancer of the protective layers of the brain. These reported associations have been strongest among prolonged users (i.e., more th...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2eb2d419-efd2-5a10-a230-4e2ecb548a26
DOI: 10.1101/2025.06.26.25330350

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest

The association between medroxyprogesterone acetate exposure and cerebral meningioma among a Medicaid populationDOI 10.1101/2025.06.26.25330350Read

Progestin-associated shift of meningioma mutational landscape.Semantic proximity Read

A proteogenomic RNA processing mechanism drives sex differences in meningiomaSemantic proximity Read

Protective effects of testosterone replacement therapy on brain tumor outcomes: the Mayo Clinic ExperienceSemantic proximity Read

Occurrence, regulation, and significance of progesterone receptors in human meningiomaSemantic proximity Read

Occupational Histories in Neuropathologically Confirmed Multiple System AtrophySemantic proximity Read

The risk of developing a meningioma during and after pregnancySemantic proximity Read

Effect of short-term prescription opioids on DNA methylation of the OPRM1 promoterSemantic proximity Read

Current treatment options for meningioma.Semantic proximity Read